NCT03365193

Brief Summary

Infective endocarditis is a potentially lethal disease that has undergone major changes over the last decades. The Duke Criteria are recommended for evaluation of probability of presence of infective endocarditis by current ESC guidelines. However, since the introduction of Duke criteria in 1994, characteristics of patients presenting with potential infective endocarditis have substantially changed, especially in tertiary care facilities, towards a high proportion of patients with immune deficiency (caused by illness or medically induced), critically ill patients, patients with prosthetic valves and patients with long-lasting intensive care treatment. Likewise, with the increasing interventional therapy of structural heart disease and device implantation in older and multi-morbid patient cohorts, the frequency of endocarditis on prosthetic material and devices increased over the last decades. While Duke criteria overall misclassify a substantial proportion of patients with endocarditis, Duke criteria are difficult to apply in these patients because of lower sensitivity. Therefore, several modifications of the Duke criteria have been proposed. In addition, the uncertainty regarding potential infective endocarditis of treating physicians due to clinical characteristics of their patients leads to an increase in requests for transthoracic and transesophageal echocardiography, overcoming echocardiography laboratories. In the present study the investigators aim to identify (I) the precision of the Duke score in predicting presence of infective endocarditis in patients examined at the echocardiography laboratory of the West German Heart Center (II) determine characteristics, not including echocardiography that are associated with increased risk of infective endocarditis, justifying transesophageal echocardiography examination and (III) establish scoring algorithms to help treating physicians to assess the risk of endocarditis in severely diseased patient cohorts prior to echocardiography examinations and to avoid unnecessary echo exams.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
263

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 1, 2017

Completed
Same day until next milestone

Study Start

First participant enrolled

December 1, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 7, 2017

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 3, 2019

Completed
2.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

October 7, 2021

Completed
Last Updated

October 8, 2021

Status Verified

October 1, 2021

Enrollment Period

1.4 years

First QC Date

December 1, 2017

Last Update Submit

October 7, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Infective Endocarditis

    Defined by an external clinical event committee

    From date of enrollment until hospital discharge, assessed up to 30 days

Secondary Outcomes (1)

  • Presence of signs of infective endocarditis on transesophageal echocardiography as defined by judgement of the examining physician.

    At echocardiography examination.

Interventions

Standard transesophageal echocardiography will be performed as clinically indicated by treating physicians.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study will include patients with clinical indication for transesophageal echocardiography, as by decision of treating physicians.

You may qualify if:

  • patients referred for echocardiographic assessment of suspected endocarditis

You may not qualify if:

  • Unwillingness to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Essen

Essen, North Rhine-Westphalia, 4, Germany

Location

Related Publications (1)

  • Mahabadi AA, Mahmoud I, Dykun I, Totzeck M, Rath PM, Ruhparwar A, Buer J, Rassaf T. Diagnostic value of the modified Duke criteria in suspected infective endocarditis -The PRO-ENDOCARDITIS study. Int J Infect Dis. 2021 Mar;104:556-561. doi: 10.1016/j.ijid.2021.01.046. Epub 2021 Jan 27.

MeSH Terms

Conditions

Endocarditis

Interventions

Echocardiography, Transesophageal

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

EchocardiographyCardiac Imaging TechniquesDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisUltrasonographyHeart Function TestsDiagnostic Techniques, Cardiovascular

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, coordinator cardiac trial unit, Principal Investigator

Study Record Dates

First Submitted

December 1, 2017

First Posted

December 7, 2017

Study Start

December 1, 2017

Primary Completion

May 3, 2019

Study Completion

October 7, 2021

Last Updated

October 8, 2021

Record last verified: 2021-10

Locations